Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TXNRD1 | Q16881 | 10/20 | 0.43 |
| ▸ | RAB9A | P51151 | 4/20 | 0.42 |
| ▸ | NPC1 | O15118 | 3/20 | 0.42 |
| ▸ | RECQL | P46063 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.40 |
| ▸ | MAPT | P10636 | 3/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | GSR | P00390 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.38 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.38 |
| ▸ | GFER | P55789 | 1/20 | 0.38 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30021226 | 1.00 | TXNRD1 (0.43) | TXNRD1RAB9ANPC1RECQLSMN1; SMN2 | |
| SCHEMBL26087592 | 0.84 | TXNRD1 (0.46) | TXNRD1RAB9ANPC1RECQLSMN1; SMN2 | |
| SCHEMBL1313407 | 0.83 | MAOA (0.49) | TXNRD1RAB9ANPC1RECQLKMT2A | |
| SCHEMBL27772658 | 0.81 | TXNRD1 (0.41) | TXNRD1RAB9ANPC1RECQLALDH1A1 | |
| SCHEMBL31703573 | 0.81 | NPC1 (0.37) | TXNRD1RAB9ANPC1RECQLSMN1; SMN2 | |
| SCHEMBL1428159 | 0.80 | TXNRD1 (0.58) | TXNRD1RAB9AMAPTMAPK1GSR | |
| SCHEMBL31703473 | 0.80 | NPC1 (0.36) | TXNRD1RAB9ANPC1RECQLSMN1; SMN2 | |
| SCHEMBL7836090 | 0.79 | TXNRD1 (0.56) | TXNRD1RAB9AMAPTMAPK1GSR | |
| SCHEMBL7836091 | 0.79 | TXNRD1 (0.56) | TXNRD1RAB9AMAPTMAPK1GSR | |
| SCHEMBL7836089 | 0.79 | TXNRD1 (0.56) | TXNRD1RAB9AMAPTMAPK1GSR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230115274-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | NOVARTIS PHARMA AG (CH) | 2023-04-13 | — | — | US | disclosed |
| EP-4085061-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | IFM Due, Inc. (US) | 2022-11-09 | — | — | EP | disclosed |
| CN-115279770-A | Compounds and compositions for treating diseases associated with STING activity | 艾福姆德尤股份有限公司 | 2022-11-01 | — | — | CN | disclosed |
| WO-2021138419-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | IFM DUE, INC, (US) | 2021-07-08 | — | — | WO | disclosed |
| EP-2438063-A1 | 1H-IMIDAZO[4,5-C]QUINOLINONE COMPOUNDS, USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES | Novartis AG (CH) | 2012-04-11 | — | — | EP | disclosed |
| WO-2010139747-A1 | 1H-IMIDAZO[4, 5-c]QUINOLINONE COMPOUNDS, USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES | NOVARTIS AG (CH) | 2010-12-09 | — | — | WO | disclosed |
| WO-2010139747-A1 | 1H-IMIDAZO[4, 5-c]QUINOLINONE COMPOUNDS, USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES | NOVARTIS AG (CH) | 2010-12-09 | — | — | WO | disclosed |
| US-20100311714-A1 | 1H-IMIDAZO[4,5-c]QUINOLINONE COMPOUNDS | NOVARTIS AG (CH) | 2010-12-09 | — | — | US | disclosed |
| US-20100311714-A1 | 1H-IMIDAZO[4,5-c]QUINOLINONE COMPOUNDS | NOVARTIS AG (CH) | 2010-12-09 | — | — | US | disclosed |
| US-20100311714-A1 | 1H-IMIDAZO[4,5-c]QUINOLINONE COMPOUNDS | NOVARTIS AG (CH) | 2010-12-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100311714-A1 | 1H-IMIDAZO[4,5-c]QUINOLINONE COMPOUNDS | PRKCA, ABL1, MYLK2 | TXNRD1 1492/4885RAB9A 646/4885NPC1 388/4885 |
| US-20230115274-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | STING1, CGAS, IRF3 | TXNRD1 1317/4885RAB9A 876/4885NPC1 859/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.